MedTrace Logo

Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation

NCT05699044 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2023-06-02

No results posted yet for this study

Summary

The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.

Conditions

  • Amyloid Cardiomyopathy
  • Block, AV

Interventions

DIAGNOSTIC_TEST

Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent. DPD-scintigraphy. (Echocardiography)

Sponsors & Collaborators

  • Steen Hvitfeldt Poulsen

    lead OTHER

Principal Investigators

  • Steen Poulsen, MD · Department of Cardiology, Aarhus University Hospital

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-08-01
Completion
2025-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699044 on ClinicalTrials.gov